خوف امريكا من الارهاب يجعلنا نكسب

[streamer]

قرات اليوم في احدي الصحف ان الولايات المتحدة الامريكية تلقت تحذيرات عن احتمال اقدام جماعات بالتعرض لها من خلال هجمات ارهابية جديدة وهذي المرة جرثومية وكلنا يذكر احداث الانثركس

وللعلم ومن باب مصائب قوم عن قوم فوائد فان علي سبيل المثال لا الحصر هناك شركات تنتج لقاح ضد الانثركس ومثال علي ذلك vxgn
ومن لة اطلاع علي هذا المجال ويملك فكرة كافة عن الشركات التي من الممكن ان تنشط مع اخبار من هذا النوع اتمني ان يذكرها هنا للفائدة ..
شكرا

[الهاجري]

والله ذابحك البيوتيك يا ستريمر الظاهر انك عشقت البيوتك تذكر سهمنا الغالي alth شكله رايح 4 ومن ثم 4.5

[streamer]

ههههههه اي صاج الهاجري ذابحني البيوتيك وهمتك يا بطل نبي اسهم نفس الي خبرك;)

[streamer]

ههههههههههههههههههههههههههههههه خاااافوا الانكليييييييييييييز
vxgn 6.5

[streamer]

7 دوووووولاااار

[streamer]

7.5

[streamer]

والسبب الانثركس مثل ما كان متوقع



VaxGen and Britain's Health Protection Agency Sign Preliminary Pact to Deploy Anthrax Vaccine in U.K.
Wednesday September 3, 4:31 pm ET


BRISBANE, Calif. and PORTON DOWN, England, Sept. 3 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Nasdaq: VXGN - News) and the Health Protection Agency (HPA) for England and Wales announced today that they have signed a binding letter of intent (LOI) to negotiate terms under which VaxGen would license U.K. rights to, and transfer technology for, its recombinant anthrax vaccine candidate (rPA102) to HPA. The agreement would give HPA the right to manufacture the vaccine in the United Kingdom as well as to market the vaccine in the United Kingdom and possibly other territories.
The LOI envisages that VaxGen will continue to manufacture rPA102 in the U.S. and HPA would establish manufacture in the U.K., with each party acting as a back-up supplier of anthrax vaccine to the other, thus increasing the supply security of this strategically important product. Earlier this year, VaxGen completed construction and commissioning of its U.S. manufacturing facility with a capacity of approximately 100 million doses per year.

Under the terms of the LOI, HPA would be responsible for transfer of the manufacturing process and licensure of the product in the U.K. VaxGen would receive a royalty on sales of rPA102, if it is approved by the U.K. regulatory authority. This royalty may be supplemented by reciprocal rights to product technologies under development by HPA.

The 12-month LOI is subject to extensions by mutual agreement of VaxGen and HPA. A definitive agreement will be subject to approval from the U.S. and U.K. governments and conclusion of a license agreement between VaxGen and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) regarding underlying intellectual property. VaxGen is developing the rPA102 anthrax vaccine candidate under contract from the U.S. National Institute of Allergy and Infectious Diseases (NIAID).

VaxGen selected HPA as its partner in this effort based on HPA's extensive experience with anthrax and a successful working relationship developed over the course of VaxGen's work under its NIAID contract to develop rPA102. HPA is the manufacturer of the current U.K. anthrax vaccine.